Evidence map›Paper›PMID 40861476›Full record

ArticleFrontiers in immunology2025

Clone-specific residue changes at multiple positions are associated with amyloid formation by antibody light chains.

Gareth J Morgan, Tatiana Prokaeva

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gareth J MorganBoston University Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, United States.
Tatiana ProkaevaBoston University Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Systemic AL amyloidosis is caused by deposition of monoclonal antibody light chains (LC) as insoluble amyloid fibrils in multiple tissues, leading to irreversible and eventually fatal organ damage. Each patient has a unique LC sequence that appears to define its propensity to aggregate. The complexity and diversity of LC sequences has impeded efforts to understand why some LCs aggregate to cause disease while others do not. Methods: We investigated residue changes, relative to the inferred precursor germline sequences, in monoclonal LCs associated with AL amyloidosis and multiple myeloma (MM), derived from the AL-Base resource. Consensus matrices, calculated using healthy polyclonal repertoire sequences from Observed Antibody Space (OAS), were used to determine the relative frequency of each residue in the monoclonal LC sequences. Results: A subset of residues observed in AL-associated LCs was uncommon in the healthy repertoire, but these residues were highly diverse and were also observed in MM-associated LCs. We identified multiple positions that more frequently harbor uncommon residues in AL-associated LCs than OAS-derived LCs, including several positions that have previously been identified. However, each individual residue change occurs in only a small fraction of LCs, indicating that many types of residue change can contribute to disease. Furthermore, positions where residue changes occur most frequently were not enriched in amyloidosis-associated residues. Discussion: These data provide a framework for future investigations into sequence determinants of amyloid propensity, supporting efforts towards earlier recognition and diagnosis of AL amyloidosis.

Indexed as

AmyloidImmunoglobulin Light-chain AmyloidosisImmunoglobulin Light ChainsAmino Acid SequenceHumansMultiple MyelomaAmyloidImmunoglobulin Light Chainsamyloidogenesisimmunoglobulin light chainsplasma cellsprotein aggregationrare diseasesomatic hypermutationsystemic AL amyloidosis

Identifiers

PMID40861476
PMCPMC12375997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.